Effects of entecavir and Shenxian Yiganling combination therapy on patients with HBeAg-positive chronic hepatitis B for 48 weeks.
- Author:
Tao ZHANG
1
;
Ya WANG
;
Ke-Wei SUN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antiviral Agents; therapeutic use; DNA, Viral; blood; Drug Therapy, Combination; Drugs, Chinese Herbal; therapeutic use; Female; Guanine; analogs & derivatives; therapeutic use; Hepatitis B e Antigens; blood; Hepatitis B, Chronic; blood; drug therapy; Humans; Male; Middle Aged; Phytotherapy; Prospective Studies; Treatment Outcome; Young Adult
- From: Chinese Journal of Integrated Traditional and Western Medicine 2012;32(2):180-182
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate of the efficacy and safety of entecavir (ETV) combined with Shenxian Yiganling (SY) versus ETV therapy on patients with HBeAg-positive chronic hepatitis B (CHB) for 48 weeks.
METHODSOne hundred and sixty-four CHB patients were assigned to two groups with the cohort study: the ETV combined with SY treatment group and the ETV control group. The alanine aminotransferase (ALT), the undetectable HBV DNA level, and HBeAg negative conversion rate, and HBeAg serological negative conversion rate were observed before and after treatment.
RESULTSAt week 48, there was no significant difference in the normalization of ALT levels (70.00% vs 67.61%, P > 0.05) and undetectable HBV DNA levels (72.50% vs 73.24%, P > 0.05) between the two groups. There was significant difference in the HBeAg negative conversion rate (39.44% vs 23.75%) and HBeAg serological negative conversion rate (32.39% vs 15.00%) (both P < 0.05).
CONCLUSIONETV combined with SY promoted the HBeAg serological negative conversion rate possibly through the recovery of the immune functions.
